

APR 22 2002

K 020218

## Summary of Safety and Effectiveness

Company Name: Nicolet Biomedical  
5225 Verona Road  
Madison, WI 53711

Contact: Glen Hermanson, Manager of Standards and Compliance  
Phone: 608 441-2065  
Fax: 608 441-2007

Summary Date: January 17, 2002

Trade Name: SNAP

Common Name: EEG Monitor

Classification Name: 21 CFR 882.1400; Product Code: GWQ

Predicate Device(s):

510(k) Number: K952347  
Manufacture: ASPECT Medical Inc.  
Trade Name: A-1050 EEG Monitor

510(k) Number: K991054  
Manufacture: Nicolet Biomedical  
Trade Name: Bravo Endeavor Multi-Modality System

### **1.0 Description of Device**

The SNAP device records and displays a processed EEG parameter called the SNAP Index, records and displays a time based trend of the SNAP Index and displays a real time EEG signal. The SNAP system has four significant components:

1. A Visor SNAP module, which is inserted into the springboard slot of a Handspring Visor handheld computer.
2. A disposable, single patient use SNAP Electrode for acquiring the EEG signal.
3. A patient cable which connects the Visor SNAP module to the patient electrode.

4. SNAP personal computer application software, which is provided for use on personal computers operating with Microsoft Windows® operating systems.

## **2.0 Intended Use**

The intended use of the SNAP device is consistent with the classification 21 CFR 882.1400, Electroencephalograph:

"An electroencephalograph is a device used to measure and record the electrical activity of the patient's brain obtained by placing two or more electrodes on the head."

The SNAP device is intended to monitor a patient's EEG. A derived EEG measure, the SNAP Index, indicates the patient's brain activity level. The SNAP device is a prescription device used under the guidance and interpretation of a licensed medical professional.

## **3.0 Technological**

The technology of the SNAP device is equivalent to other EEG monitoring devices. The EEG signal is acquired in analog format, digitized and presented to the user for interpretation. The SNAP device includes an EEG trended parameter of the power spectrum of the EEG signal, SNAP Index.

The SNAP device is incorporated with a handheld computer, the Visor. A custom SNAP Electrode is provided for the convenience of the user in applying three monitoring electrodes.

## **4.0 Conclusions**

The indications, intended use and technology of the SNAP device is substantially equivalent to the predicate devices. No new questions of safety or effectiveness are raised.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Nicolet Biomedical, Inc.  
c/o Mr. Gary Syring  
Quality and Regulatory Associates, LLC  
800 Levanger Lane  
Stoughton, WI 53589

APR 22 2002

Re: K020218  
Trade/Device Name: SNAP  
Regulation Number: 882.1400  
Regulation Name: Electroencephalograph  
Regulatory Class: II  
Product Code: GWQ  
Dated: January 21, 2002  
Received: January 22, 2002

Dear Mr. Syring:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Gary Syring

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "for Mark A. Witten", is written over the typed name.

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): K 020218

Device Name: SNAP


Indications For Use:

The SNAP device is intended to monitor a patient's EEG. A derived EEG measure, the SNAP Index, indicates the patient's brain activity level. The SNAP device is used under the guidance and interpretation of a licensed medical professional.

(PLEASE: DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

(Optional Format 3-10-98)

  
(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices

510(k) Number K 020218